Debiopharm awards the profitable scientists for the JCA (Japanese Cancer Association) Award for modern, disruptive, and translational oncology analysis
LAUSANNE, Switzerland , Oct. 3, 2022 /PRNewswire/ — Debiopharm (www.debiopharm.com), a Swiss-based world biopharmaceutical firm, at present introduced the 2 winners of JCA Mauvernay Award for breakthrough Japanese oncology analysis tasks in 2 classes: Innovative and/or Disruptive Research – Dr. Akihide Yoshimi and for Translational Research – Prof. Mamiko Sakata-Yanagimoto. The winners have been honored with trophies and a financial prize through the stay occasion of the 81st Annual Meeting of the Japanese Cancer Association (JCA) on Saturday, October 1st in Yokohama, Japan by Prof. Hideyuki Saya President of the JCA and Thierry Mauvernay, President of Debiopharm, and Bertrand Ducrey CEO of Debiopharm.
“Japan and Switzerland share a variety of similar values such as commitment to excellence and professional diligence. With these values, we can maximize the chances that the next generation of drugs could result from collaboration between these two countries.” expressed Thierry Mauvernay, President of Debiopharm. “Together with the JCA, Debiopharm hopes to encourage young scientists such as Drs Yoshimi and Sakata-Yanagimoto, to transfer their innovative research to the clinic and to the benefit of worldwide patients rapidly.”
“The previous winners of the Mauvernay Award have immediately become very well-known scientists in our country, becoming professors and leaders in significant institutes. Therefore, I would say that the Mauvernay Award is definitely a huge step for young cancer research scientists in our country.” said Prof. Hideyuki Saya, President of the JCA.
Dr. Akihide Yoshimi’s disruptive analysis on the National Cancer Center Research Institute, is geared toward understanding and focusing on aberrant RNA splicing in hematological malignancies. He has contributed to the invention of aberrant occasions on this course of in tumor cells, recognized key alterations in a number of splicing components (SF) and supplied insights into aberrant splicing and its affiliation with key oncogenes (corresponding to isocitrate dehydrogenase (IDH) and myelocytomatosis (Myc)). This work inside an rising area might have necessary organic in addition to therapeutic implications for affected person with SF mutant hematologic malignancies (e.g. in acute myeloid leukemia (AML), power lymphocytic leukemia (CLL), power myelomonocytic leukemia (CMML) and myelodysplastic syndrome (MDS)).
Prof. Mamiko Sakata-Yanagimoto’s translational analysis on the Medicine Faculty of the University of Tsukuba is providing new insights into focusing on intractable lymphomas with a sublime utility of gene expression evaluation within the aggressive angioimmunoblastic lymphoma (AITL). Her analysis began with the characterization of sequence of occasions between TET2 and RHOA mutations within the AITL affected person samples (now included within the diagnostic standards), continued with the identification of recent actionable targets within the illness (RHOA/Vav1) and is at present targeted on testing within the clinic therapeutic choices utilizing dasatinib to deal with these sufferers.
The JCA-Mauvernay Award
Since 2005, the Japanese Cancer Association (JCA) and Debiopharm have co-organized the ‘JCA-Mauvernay Award’. This prize illustrates the curiosity that drives researchers in addition to the scientific cooperation between Japan and Switzerland. It goals to acknowledge the excellent achievements within the area of oncology amongst Japanese researchers, in each the elemental and the medical facets. The award has a complete worth of CHF 25’000.
Debiopharm’s dedication to sufferers
Debiopharm develops modern therapies that focus on excessive unmet medical wants in oncology and infectious illnesses. Bridging the hole between disruptive discovery merchandise and real-world affected person attain, we establish high-potential compounds and applied sciences for in-licensing, clinically display their security and efficacy after which choose giant pharmaceutical commercialization companions to maximise affected person entry globally.
For extra info, please go to www.debiopharm.com
We are on Twitter. Follow us @DebiopharmInformation at http://twitter.com/DebiopharmNews
Debiopharm Contact
Dawn Haughton-Bonine
Communication Manager
[email protected]
Tel: +41 (0)21 321 01 11
View unique content material:https://www.prnewswire.co.uk/news-releases/debiopharm-reinforces-the-bond-between-swiss-and-japanese-cancer-research-with-the-2022-jca-mauvernay-award-ceremony-301638251.html
